Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label rollover extension of iptacopan in paroxysmal nocturnal hemoglobinuria
CTR20222669Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Iptacopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Novartis. Primary endpoint: Safety assessment. Started Nov 2022; status: completed.
02
Drugs
Iptacopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on CTR20222669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222669.